230
This work aimed to explore what ethical issues should one consider when deciding
whether and how to use biomedical means of moral modification. Chapters 1-4
focused on the conceptual issues and the plausibility of MB. Chapters 5-7
addressed
objections and doubts raised about the ethical desirability of MB. Chapters 7 and 8
examined arguments related to the potential impact of MB on freedom and moral
agency.
Chapter 1 addressed the question of what can be considered to be moral
enhancement by examining the ambiguity of the phrase ‘moral enhancement’ and
clarifying what can be meant by ‘moral’ and ‘enhancement’. In section 1.2 I have
outlined the three uses of ‘moral’ and proposed that ‘moral enhancement’ can refer
to any enhancement that is morally desirable, interventions aimed at making
morally better agents and enhancement in the moral sphere that is beneficial to the
agent. In section 1.3 I have outlined the objections to the normative strength of the
treatment-enhancement distinction and, finding
the arguments convincing, proposed
to understand ‘enhancement’ widely as ‘improvement’ and proceeded on this basis.
This meant that the ethical assessment of MB might include MB utilized both in
medical-therapeutic and non-therapeutic contexts. In section 1.4 I have argued that
the additional level of moral consideration includes the assessment of the overall
moral permissibility of the specific way MB is used.
Thus, in this first conceptual chapter I have proposed that we consider ‘moral
enhancement’ widely, as biomedical interventions that modify the moral sphere in
addition to those aimed at improving moral agency specifically. I have also
proposed that in the debates sprang out by the prospects of modifying the
underpinnings
of morality and sociality, we should also attend to cases where the
modification does not aim at creating morally better people, but rather is done on
the basis of other, e.g. prudential, considerations. This
means that an enhancing
intervention in the sphere relevant to moral function may bring a dis-enhancement
in moral agency and questions about what is and is not conducive to morality in
given context and for certain occupations (e.g. military personnel, doctors, care
professionals). I have proposed that the use of the term ‘biomedical moral
modification’ (MB) might be more appropriate, given various possible goals of
such modifications and pending
the assessment of the numerous, often context-
231
dependent, factors that influence the assessment whether a given intervention is
morally desirable.
In Chapter 2, I have asked whether specifically biomedical means of modifying the
moral sphere are likely to be effective, and what kinds of effects can be expected
after MB and thus what goals are in this context reasonable. I argued that MB is
plausible, but that we should revise our goals and expectations in discussion MB.
The aims such as
eliminating large scale harm, reducing poverty or addressing
climate change (Rifkin, 2010; Persson and Savulescu, 2008) mean that we expect
too much of MB. Instead, I proposed that we see MB similarly to biomedical
cognitive enhancement: as a small but significant improvement in underlying
cognitive or affective processes that will help us to better do what we want. With
our goals revised
and expectations adjusted, the examination of the effects of
oxytocin on social function revealed that sometimes the effects of biomedical
modification can be significant. This gives a
Do'stlaringiz bilan baham: